Skip to content

An ascending single dose, randomised, double-blind, placebo-controlled phase 1 study of the tolerability, pharmacokinetics and pharmacodynamics of AJM300 in healthy adult males in the fasting and fed states

An ascending single dose, randomised, double-blind, placebo-controlled phase 1 study of the tolerability, pharmacokinetics and pharmacodynamics of AJM300 in healthy adult males in the fasting and fed states

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1080224924
Enrollment
62
Registered
2019-10-16
Start date
2003-04-14
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult Subjects

Interventions

Sponsors

EA Pharma Co., Ltd
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Main inclusion criteria - Able to provide written informed consent. - Male subjects aged>=18 to < 55 years and in good health as determined at screening. - BMI within 18-28 kg/m2. - Able to communicate well with the Investigator and comply with the study requirements.

Exclusion criteria

Exclusion criteria: Main exclusion criteria - Any medical or surgical condition which might significantly alter drug absorption,distribution metabolism of excretion. - Concurrent gastrointestinal disease. - History of drug allergy. - History of drug or alcohol abuse. - Current smokers or cessation of smoking within 3 months of dosing. - Use of any prescription medication within 28 days prior to dosing and over-the counter medication and vitamins within 3 days prior to dosing. - Participation in any clinical study within 3 months prior to dosing.

Design outcomes

Primary

MeasureTime frame
safety - Physical examination results - Vital signs - ECGs - Safety laboratory test results - CRP - Adverse events

Secondary

MeasureTime frame
pharmacokinetics AJM300 and metabolites

Countries

Europe

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026